Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma
- Author
- Ahmet Krasniqi, Matthias D'Huyvetter, Catarina Xavier, Kevin Van der Jeught, Serge Muyldermans, José Van Der Heyden (UGent) , Tony Lahoutte, Jan Tavernier (UGent) and Nick Devoogdt
- Organization
- Keywords
- Y-90 IBRITUMOMAB TIUXETAN, B-CELL LYMPHOMA, PHASE-II TRIAL, FOLLICULAR LYMPHOMA, LOW-GRADE, MONOCLONAL-ANTIBODY, ANTI-HER2 NANOBODY, CHOP CHEMOTHERAPY, FOLLOW-UP, RITUXIMAB
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- binary/octet-stream
- |
- 1.28 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8554379
- MLA
- Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, et al. “Theranostic Radiolabeled anti-CD20 sdAb for Targeted Radionuclide Therapy of non-Hodgkin Lymphoma.” MOLECULAR CANCER THERAPEUTICS 16.12 (2017): 2828–2839. Print.
- APA
- Krasniqi, A., D’Huyvetter, M., Xavier, C., Van der Jeught, K., Muyldermans, S., Van Der Heyden, J., Lahoutte, T., et al. (2017). Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. MOLECULAR CANCER THERAPEUTICS, 16(12), 2828–2839.
- Chicago author-date
- Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, Kevin Van der Jeught, Serge Muyldermans, José Van Der Heyden, Tony Lahoutte, Jan Tavernier, and Nick Devoogdt. 2017. “Theranostic Radiolabeled anti-CD20 sdAb for Targeted Radionuclide Therapy of non-Hodgkin Lymphoma.” Molecular Cancer Therapeutics 16 (12): 2828–2839.
- Chicago author-date (all authors)
- Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, Kevin Van der Jeught, Serge Muyldermans, José Van Der Heyden, Tony Lahoutte, Jan Tavernier, and Nick Devoogdt. 2017. “Theranostic Radiolabeled anti-CD20 sdAb for Targeted Radionuclide Therapy of non-Hodgkin Lymphoma.” Molecular Cancer Therapeutics 16 (12): 2828–2839.
- Vancouver
- 1.Krasniqi A, D’Huyvetter M, Xavier C, Van der Jeught K, Muyldermans S, Van Der Heyden J, et al. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. MOLECULAR CANCER THERAPEUTICS. 2017;16(12):2828–39.
- IEEE
- [1]A. Krasniqi et al., “Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma,” MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 12, pp. 2828–2839, 2017.
@article{8554379,
author = {Krasniqi, Ahmet and D'Huyvetter, Matthias and Xavier, Catarina and Van der Jeught, Kevin and Muyldermans, Serge and Van Der Heyden, José and Lahoutte, Tony and Tavernier, Jan and Devoogdt, Nick},
issn = {1535-7163},
journal = {MOLECULAR CANCER THERAPEUTICS},
keywords = {Y-90 IBRITUMOMAB TIUXETAN,B-CELL LYMPHOMA,PHASE-II TRIAL,FOLLICULAR LYMPHOMA,LOW-GRADE,MONOCLONAL-ANTIBODY,ANTI-HER2 NANOBODY,CHOP CHEMOTHERAPY,FOLLOW-UP,RITUXIMAB},
language = {eng},
number = {12},
pages = {2828--2839},
title = {Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma},
url = {http://dx.doi.org/10.1158/1535-7163.mct-17-0554},
volume = {16},
year = {2017},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: